In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

Pfizer's PFE non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and ...

Stocks like Pfizer, Amgen, Johnson & Johnson, and Eli Lilly & Co. were among others which opened lower after the US stock market opened on Wednesday. Pfizer Inc. shares are currently trading 2.56 ...

Pharmaceutical giant Pfizer sold its longtime San Diego campus to a life science-focused commercial real estate company in one of the largest deals of the past year. Pfizer sold the five ...

Pfizer Inc.’s longtime chief scientist is joining Blackstone Inc. to advise the private equity giant on its investments into advanced new medicines. Mikael Dolsten, who retired from Pfizer late ...

Pfizer and AbbVie shares declined more than 4%, Merck dropped almost 4%, and Eli Lilly pulled back over 3% in early trading. Daily Merck & Company, Inc. Dow pharmaceutical components are leading ...

Pfizer is one of the world’s largest pharmaceutical companies, with annual sales above $63 billion in 2024. Shares are down approximately 20% year-to-date. UBS analyst Trung Huynh maintained ...

New York is part of a $335 million multistate settlement with a spin-off company of the pharmaceutical giant Pfizer for its role in the opioid epidemic over the last twenty years. The leaders of ...

Pfizer‘s stock has nosedived over 63% since its post-pandemic peak, scaring off investors like it’s contagious. Despite the brutal dip, Pfizer still dishes out a juicy 7.5% dividend, hinting at ...

While currently approved therapies for COVID-19 like Paxlovid target a critical coronavirus protein known as Mpro, WEHI researchers identified another protein, termed PLpro as a promising drug target ...